These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 21618986)

  • 41. Differential monoaminergic, neuroendocrine and behavioural responses after central administration of corticotropin-releasing factor receptor type 1 and type 2 agonists.
    de Groote L; Peñalva RG; Flachskamm C; Reul JM; Linthorst AC
    J Neurochem; 2005 Jul; 94(1):45-56. PubMed ID: 15953348
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Corticotropin-releasing hormone receptor 1 antagonist blocks brain-gut activation induced by colonic distention in rats.
    Saito K; Kasai T; Nagura Y; Ito H; Kanazawa M; Fukudo S
    Gastroenterology; 2005 Nov; 129(5):1533-43. PubMed ID: 16285953
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats.
    Nakade Y; Fukuda H; Iwa M; Tsukamoto K; Yanagi H; Yamamura T; Mantyh C; Pappas TN; Takahashi T
    Am J Physiol Gastrointest Liver Physiol; 2007 Apr; 292(4):G1037-44. PubMed ID: 17158256
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Role of corticotropin-releasing factor (CRF) receptors in the anorexic syndrome induced by CRF.
    Pelleymounter MA; Joppa M; Carmouche M; Cullen MJ; Brown B; Murphy B; Grigoriadis DE; Ling N; Foster AC
    J Pharmacol Exp Ther; 2000 Jun; 293(3):799-806. PubMed ID: 10869378
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Design, synthesis, and SAR of 2-dialkylamino-4-arylpyrimidines as potent and selective corticotropin-releasing factor(1) (CRF(1)) receptor antagonists.
    Huang CQ; Grigoriadis DE; Liu Z; McCarthy JR; Ramphal J; Webb T; Whitten JP; Xie MY; Chen C
    Bioorg Med Chem Lett; 2004 May; 14(9):2083-6. PubMed ID: 15080983
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Characterization of corticotropin-releasing factor receptor-mediated adenylate cyclase activity in the rat central nervous system.
    Battaglia G; Webster EL; De Souza EB
    Synapse; 1987; 1(6):572-81. PubMed ID: 2843998
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of CRF2 receptor antagonists on rat conditioned fear responses and c-Fos and CRF expression in the brain limbic structures.
    Skórzewska A; Lehner M; Hamed A; Wisłowska-Stanek A; Turzyńska D; Sobolewska A; Płaźnik A
    Behav Brain Res; 2011 Aug; 221(1):155-65. PubMed ID: 21376756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The corticotropin-releasing factor (CRF)(1) receptor antagonists CP154,526 and DMP695 inhibit light-induced phase advances of hamster circadian activity rhythms.
    Gannon RL; Millan MJ
    Brain Res; 2006 Apr; 1083(1):96-102. PubMed ID: 16551464
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chronic stress-induced alterations in amygdala responsiveness and behavior--modulation by trait anxiety and corticotropin-releasing factor systems.
    Sandi C; Cordero MI; Ugolini A; Varea E; Caberlotto L; Large CH
    Eur J Neurosci; 2008 Nov; 28(9):1836-48. PubMed ID: 18973598
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pyrrolo[1,2-b]pyridazines, pyrrolo[2,1-f]triazin-4(3H)-ones, and related compounds as novel corticotropin-releasing factor 1 (CRF₁) receptor antagonists.
    Saito T; Obitsu T; Kohno H; Sugimoto I; Matsushita T; Nishiyama T; Hirota T; Takeda H; Matsumura N; Ueno S; Kishi A; Kagamiishi Y; Nakai H; Takaoka Y
    Bioorg Med Chem; 2012 Jan; 20(2):1122-38. PubMed ID: 22196514
    [TBL] [Abstract][Full Text] [Related]  

  • 51. In vitro and in vivo metabolism and pharmacokinetics of BMS-562086, a potent and orally bioavailable corticotropin-releasing factor-1 receptor antagonist.
    Zhou L; Dockens RC; Liu-Kreyche P; Grossman SJ; Iyer RA
    Drug Metab Dispos; 2012 Jun; 40(6):1093-103. PubMed ID: 22381334
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Synthesis and structure-activity relationships of pyrazolo[1,5-a]pyridine derivatives: potent and orally active antagonists of corticotropin-releasing factor 1 receptor.
    Takahashi Y; Hibi S; Hoshino Y; Kikuchi K; Shin K; Murata-Tai K; Fujisawa M; Ino M; Shibata H; Yonaga M
    J Med Chem; 2012 Jun; 55(11):5255-69. PubMed ID: 22587443
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery and preclinical characterization of 1-methyl-3-(4-methylpyridin-3-yl)-6-(pyridin-2-ylmethoxy)-1H-pyrazolo-[3,4-b]pyrazine (PF470): a highly potent, selective, and efficacious metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulator.
    Zhang L; Balan G; Barreiro G; Boscoe BP; Chenard LK; Cianfrogna J; Claffey MM; Chen L; Coffman KJ; Drozda SE; Dunetz JR; Fonseca KR; Galatsis P; Grimwood S; Lazzaro JT; Mancuso JY; Miller EL; Reese MR; Rogers BN; Sakurada I; Skaddan M; Smith DL; Stepan AF; Trapa P; Tuttle JB; Verhoest PR; Walker DP; Wright AS; Zaleska MM; Zasadny K; Shaffer CL
    J Med Chem; 2014 Feb; 57(3):861-77. PubMed ID: 24392688
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Preclinical characterization of substituted 6,7-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-8(5H)-one P2X7 receptor antagonists.
    Ameriks MK; Ao H; Carruthers NI; Lord B; Ravula S; Rech JC; Savall BM; Wall JL; Wang Q; Bhattacharya A; Letavic MA
    Bioorg Med Chem Lett; 2016 Jan; 26(2):257-261. PubMed ID: 26707399
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Potential CRF1R PET imaging agents: 1-fluoroalkylsubstituted 5-halo-3-(arylamino)pyrazin-2(1H)-ones.
    Denhart DJ; Zuev D; Ditta JL; Hartz RA; Ahuja VT; Mattson RJ; Huang H; Mattson GK; Zueva L; Nielsen JM; Kozlowski ES; Lodge NJ; Bronson JJ; Macor JE
    Bioorg Med Chem Lett; 2013 Apr; 23(7):2052-5. PubMed ID: 23465610
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis, binding affinity, radiolabeling, and microPET evaluation of 4-(2-substituted-4-substituted)-8-(dialkylamino)-6-methyl-1-substituted-3,4-dihydropyrido[2,3-b]pyrazin-2(1H)-ones as ligands for brain corticotropin-releasing factor type-1 (CRF1) receptors.
    Stehouwer JS; Bourke CH; Owens MJ; Voll RJ; Kilts CD; Goodman MM
    Bioorg Med Chem Lett; 2015 Nov; 25(22):5111-4. PubMed ID: 26456805
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative biotransformation of pyrazinone-containing corticotropin-releasing factor receptor-1 antagonists: minimizing the reactive metabolite formation.
    Zhuo X; Hartz RA; Bronson JJ; Wong H; Ahuja VT; Vrudhula VM; Leet JE; Huang S; Macor JE; Shu YZ
    Drug Metab Dispos; 2010 Jan; 38(1):5-15. PubMed ID: 19833844
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Synthesis and evaluation of prodrugs of corticotropin-releasing factor-1 (CRF
    Hartz RA; Vrudhula VM; Ahuja VT; Grace JE; Lodge NJ; Bronson JJ; Macor JE
    Bioorg Med Chem Lett; 2017 Mar; 27(6):1360-1363. PubMed ID: 28223020
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design and Synthesis of Benzimidazoles As Novel Corticotropin-Releasing Factor 1 Receptor Antagonists.
    Mochizuki M; Kori M; Kobayashi K; Yano T; Sako Y; Tanaka M; Kanzaki N; Gyorkos AC; Corrette CP; Cho SY; Pratt SA; Aso K
    J Med Chem; 2016 Mar; 59(6):2551-66. PubMed ID: 26901666
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Synthesis and evaluation of imidazo[1,5-a]pyrazines as corticotropin releasing hormone receptor ligands.
    Hartz RA; Gilligan PJ; Nanda KK; Tebben AJ; Fitzgerald LW; Miller K
    Bioorg Med Chem Lett; 2002 Feb; 12(3):291-4. PubMed ID: 11814780
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.